$ARMP
Armata Pharmaceuticals, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022003845 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $989.0K $4.474M $504.0K
YoY Change 96.23% 443.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.223M $8.281M $877.0K
YoY Change 153.48% 20.61% -7.68%
% of Gross Profit
Research & Development $4.814M $20.02M $4.980M
YoY Change -3.33% 38.57% 198.2%
% of Gross Profit
Depreciation & Amortization $277.0K $1.200M $274.0K
YoY Change 1.09% 9.09% -9.27%
% of Gross Profit
Operating Expenses $7.037M $28.30M $5.857M
YoY Change 20.15% 26.27% 123.55%
Operating Profit -$23.82M
YoY Change 10.35%
Interest Expense $1.000K $100.0K -$177.0K
YoY Change -100.56% -83.33% -11.5%
% of Operating Profit
Other Income/Expense, Net $667.0K $1.106M
YoY Change -212.29% 1.65%
Pretax Income -$6.047M -$23.16M -$6.624M
YoY Change -8.71% 4.39% 44.31%
Income Tax
% Of Pretax Income
Net Earnings -$6.047M -$23.16M -$6.624M
YoY Change -8.71% 4.39% 44.31%
Net Earnings / Revenue -611.43% -517.55% -1314.29%
Basic Earnings Per Share -$0.96
Diluted Earnings Per Share -$229.7K -$0.96 -$359.3K
COMMON SHARES
Basic Shares Outstanding 27.09M 24.10M
Diluted Shares Outstanding 24.10M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.29M $10.29M $9.649M
YoY Change 6.62% 6.62% 59.94%
Cash & Equivalents $10.29M $10.29M $9.649M
Short-Term Investments
Other Short-Term Assets $4.707M $4.707M $1.197M
YoY Change 293.23% 293.23% 92.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.00M $15.00M $10.85M
YoY Change 38.25% 38.25% 62.98%
LONG-TERM ASSETS
Property, Plant & Equipment $2.220M $38.07M $2.047M
YoY Change 8.45% 196.58% -51.44%
Goodwill $3.490M $3.490M
YoY Change 0.0%
Intangibles $10.26M $10.26M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $1.755M $2.955M $887.0K
YoY Change 97.86% 41.59% 6.23%
Total Long-Term Assets $54.77M $54.77M $28.67M
YoY Change 91.05% 91.05% 52.53%
TOTAL ASSETS
Total Short-Term Assets $15.00M $15.00M $10.85M
Total Long-Term Assets $54.77M $54.77M $28.67M
Total Assets $69.77M $69.77M $39.52M
YoY Change 76.56% 76.56% 55.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.138M $1.138M $956.0K
YoY Change 19.04% 19.04% 74.77%
Accrued Expenses $3.147M $3.147M $2.839M
YoY Change 10.85% 10.85% -15.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $722.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.814M $4.814M $6.705M
YoY Change -28.2% -28.2% 37.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.48M $36.48M $10.88M
YoY Change 235.39% 235.39% 274.81%
Total Long-Term Liabilities $36.48M $36.48M $10.88M
YoY Change 235.39% 235.39% 274.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.814M $4.814M $6.705M
Total Long-Term Liabilities $36.48M $36.48M $10.88M
Total Liabilities $44.37M $44.37M $20.66M
YoY Change 114.78% 114.78% 90.27%
SHAREHOLDERS EQUITY
Retained Earnings -$202.9M -$179.7M
YoY Change 12.89%
Common Stock $271.0K $187.0K
YoY Change 44.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.40M $25.40M $18.86M
YoY Change
Total Liabilities & Shareholders Equity $69.77M $69.77M $39.52M
YoY Change 76.56% 76.56% 55.26%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$6.047M -$23.16M -$6.624M
YoY Change -8.71% 4.39% 44.31%
Depreciation, Depletion And Amortization $277.0K $1.200M $274.0K
YoY Change 1.09% 9.09% -9.27%
Cash From Operating Activities -$8.598M -$23.58M -$6.302M
YoY Change 36.43% 29.04% 130.93%
INVESTING ACTIVITIES
Capital Expenditures -$228.0K $1.304M -$366.0K
YoY Change -37.7% 58.25% 1642.86%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$228.0K -$1.304M -$366.0K
YoY Change -37.7% 58.25% -608.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $26.32M
YoY Change 14.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.038M 25.52M 432.0K
YoY Change 1529.17% 9.94%
NET CHANGE
Cash From Operating Activities -8.598M -23.58M -6.302M
Cash From Investing Activities -228.0K -1.304M -366.0K
Cash From Financing Activities 7.038M 25.52M 432.0K
Net Change In Cash -1.788M 639.0K -6.236M
YoY Change -71.33% -84.48% 134.7%
FREE CASH FLOW
Cash From Operating Activities -$8.598M -$23.58M -$6.302M
Capital Expenditures -$228.0K $1.304M -$366.0K
Free Cash Flow -$8.370M -$24.88M -$5.936M
YoY Change 41.0% 30.3% 119.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90292
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
829-0829
CY2021 dei Security12b Title
Security12bTitle
Common Stock
CY2021 dei Trading Symbol
TradingSymbol
ARMP
CY2021 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27112299
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24104146
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16415012
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0714
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18688461
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0714
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000921114
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37544
CY2021 dei Entity Registrant Name
EntityRegistrantName
ARMATA PHARMACEUTICALS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1549568
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
4503 Glencoe Avenue
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Marina del Rey
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
38900000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30727091
CY2021 dei Auditor Name
AuditorName
Ernst & Young, LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, CA
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10288000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9649000
CY2021Q4 armp Award Receivable
AwardReceivable
2989000
CY2020Q4 armp Award Receivable
AwardReceivable
561000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1718000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
636000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
14995000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
10846000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2220000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2047000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35852000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10790000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2021Q4 us-gaap Goodwill
Goodwill
3490000
CY2020Q4 us-gaap Goodwill
Goodwill
3490000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1755000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
887000
CY2021Q4 us-gaap Assets
Assets
69768000
CY2020Q4 us-gaap Assets
Assets
39516000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1929000
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1035000
CY2020Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
563000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1509000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1551000
CY2020Q4 armp Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
722000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1940000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4814000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6705000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36480000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10877000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2021Q4 us-gaap Liabilities
Liabilities
44371000
CY2020Q4 us-gaap Liabilities
Liabilities
20659000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27112299
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18688461
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
271000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
187000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
227983000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
198372000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202857000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179702000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25397000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
18857000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69768000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39516000
CY2021 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
4474000
CY2020 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
823000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20015000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14444000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8281000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7966000
CY2021 us-gaap Operating Expenses
OperatingExpenses
28296000
CY2020 us-gaap Operating Expenses
OperatingExpenses
22410000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-23822000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-21587000
CY2021 armp Gain Loss On Extinguishment Of Paycheck Protection Program Since Inception
GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception
726000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2021 us-gaap Interest Expense
InterestExpense
64000
CY2020 us-gaap Interest Expense
InterestExpense
628000
CY2020 armp Other Other Nonoperating Income Expense
OtherOtherNonoperatingIncomeExpense
6000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
667000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-594000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-23155000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22181000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24104146
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16415012
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
14593000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22810000
CY2020 armp Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
81000
CY2020 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
8000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
87000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3475000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22181000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
18857000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26306000
CY2021 armp Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
291000
CY2021 armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
106000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
322000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2882000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-23155000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25397000
CY2021 us-gaap Profit Loss
ProfitLoss
-23155000
CY2020 us-gaap Profit Loss
ProfitLoss
-22181000
CY2021 us-gaap Depreciation
Depreciation
1169000
CY2020 us-gaap Depreciation
Depreciation
1114000
CY2021 armp Gain Loss On Extinguishment Of Paycheck Protection Program Loan
GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan
722000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2882000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3475000
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
60000
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
628000
CY2021 armp Accrued Interest For Deferred Consideration On Asset Acquisition
AccruedInterestForDeferredConsiderationOnAssetAcquisition
586000
CY2020 armp Accrued Interest For Deferred Consideration On Asset Acquisition
AccruedInterestForDeferredConsiderationOnAssetAcquisition
432000
CY2021 armp Increase Decrease In Award Receivable
IncreaseDecreaseInAwardReceivable
2428000
CY2020 armp Increase Decrease In Award Receivable
IncreaseDecreaseInAwardReceivable
467000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
184000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
544000
CY2021 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
472000
CY2020 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-760000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
499000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
803000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1950000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
994000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23575000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18270000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1304000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
824000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1304000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-824000
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1414000
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-568000
CY2020 armp Proceeds From Paycheck Protection Program
ProceedsFromPaycheckProtectionProgram
717000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26319000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22893000
CY2021 armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
613000
CY2020 armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
168000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25518000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23210000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
639000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4116000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10849000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6733000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11488000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10849000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26056000
CY2021 armp Forgiveness Related To Paycheck Protection Program
ForgivenessRelatedToPaycheckProtectionProgram
722000
CY2021 armp Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
13000
CY2020 armp Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
65000
CY2021 us-gaap Contribution Of Property
ContributionOfProperty
38000
CY2020 us-gaap Contribution Of Property
ContributionOfProperty
150000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10288000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9649000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11488000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10849000
CY2019Q2 armp Business Combination Consideration Transferred Number Of Shares Issued To Each Share Outstanding
BusinessCombinationConsiderationTransferredNumberOfSharesIssuedToEachShareOutstanding
0.6906
CY2019Q2 armp Anticipated Purchase Of Common Shares Upon Completion Of Merger
AnticipatedPurchaseOfCommonSharesUponCompletionOfMerger
10000000.0
CY2019Q2 armp Common Stock Percentage Of Aggregate Number Of Shares And Security Holders
CommonStockPercentageOfAggregateNumberOfSharesAndSecurityHolders
0.76
CY2021 us-gaap Substantial Doubt About Going Concern Managements Evaluation
SubstantialDoubtAboutGoingConcernManagementsEvaluation
The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</p>
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19210919
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12539300
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16306000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21583000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1441000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-598000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12445000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11102000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10225000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9055000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2220000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23155000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22181000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.272
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.285
CY2021 armp Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
0.008
CY2020 armp Income Tax Rate Reconciliation Permanent Differences1
IncomeTaxRateReconciliationPermanentDifferences1
0.016
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2047000
CY2021 us-gaap Depreciation
Depreciation
1200000
CY2020 us-gaap Depreciation
Depreciation
1100000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1138000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
956000
CY2021Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
529000
CY2020Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
248000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
603000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
725000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1929000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21714000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.066
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.007
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36405000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31243000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15789000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2467000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2087000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1301000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1405000
CY2021Q4 armp Deferred Tax Asset Lease Obligation
DeferredTaxAssetLeaseObligation
10631000
CY2020Q4 armp Deferred Tax Asset Lease Obligation
DeferredTaxAssetLeaseObligation
3478000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2904000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1174000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
989000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68284000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54991000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58251000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51972000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10033000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
3019000
CY2021Q4 armp Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
10033000
CY2020Q4 armp Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
3019000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3077000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3077000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13110000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6096000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3077000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3077000
CY2020Q2 armp Operating Lease Base Rent
OperatingLeaseBaseRent
1900000
CY2020Q2 armp Annual Increase In Rent Percentage
AnnualIncreaseInRentPercentage
0.03
CY2020Q2 armp Operating Lease Base Rent End Of Lease Term
OperatingLeaseBaseRentEndOfLeaseTerm
2500000
CY2020Q2 armp Lease And Rental Abatement Credit Period
LeaseAndRentalAbatementCreditPeriod
P6M
CY2020Q2 armp Lease And Rental Abatement Credit
LeaseAndRentalAbatementCredit
800000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11700000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11000000.0
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1289
CY2021Q4 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P16Y
CY2021Q4 armp Base Annual Rent To Be Paid Year Three
BaseAnnualRentToBePaidYearThree
250000
CY2021Q4 armp Maximum Allowance For Tenant Improvements Receivable
MaximumAllowanceForTenantImprovementsReceivable
7300000
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
5000000.0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1593000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2022Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
45000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1564000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4512000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5139000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5293000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
54847000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
74288000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36299000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
37989000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1509000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36480000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1100000
CY2021 us-gaap Interest Expense
InterestExpense
100000
CY2020 us-gaap Interest Expense
InterestExpense
600000
CY2019Q2 armp Revenue Expected Milestone Receivable Amount
RevenueExpectedMilestoneReceivableAmount
1500000
CY2019Q2 armp Agreement Option Fee Amount
AgreementOptionFeeAmount
1500000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16647219
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2882000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3475000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1668926
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.30
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
856150
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.77
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
99517
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
121000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15877
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
42.20
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2409682
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.64
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3630000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2409682
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.64
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3630000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
829624
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.67
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2021Q4 us-gaap Share Price
SharePrice
5.48
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2400000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2409682
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
30000
CY2021Q4 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
9748
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16647219
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19325446
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0001558370-22-003845-index-headers.html Edgar Link pending
0001558370-22-003845-index.html Edgar Link pending
0001558370-22-003845.txt Edgar Link pending
0001558370-22-003845-xbrl.zip Edgar Link pending
armp-20211231.xsd Edgar Link pending
armp-20211231x10k.htm Edgar Link pending
armp-20211231x10k003.jpg Edgar Link pending
armp-20211231x10k004.jpg Edgar Link pending
armp-20211231x10k005.jpg Edgar Link pending
armp-20211231x10k006.jpg Edgar Link pending
armp-20211231x10k007.jpg Edgar Link pending
armp-20211231x10k008.jpg Edgar Link pending
armp-20211231x10k009.jpg Edgar Link pending
armp-20211231x10k010.jpg Edgar Link pending
armp-20211231x10k011.jpg Edgar Link pending
armp-20211231x10k_htm.xml Edgar Link completed
armp-20211231xex21d1.htm Edgar Link pending
armp-20211231xex23d1.htm Edgar Link pending
armp-20211231xex31d1.htm Edgar Link pending
armp-20211231xex31d2.htm Edgar Link pending
armp-20211231xex32d1.htm Edgar Link pending
armp-20211231xex32d2.htm Edgar Link pending
armp-20211231xex4d9.htm Edgar Link pending
armp-20211231_cal.xml Edgar Link unprocessable
armp-20211231_def.xml Edgar Link unprocessable
armp-20211231_lab.xml Edgar Link unprocessable
armp-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending